Padmanabh P. Bhatt Sells 5,000 Shares of Supernus Pharmaceuticals, Inc. (SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Padmanabh P. Bhatt sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $49.86, for a total value of $249,300.00. Following the completion of the transaction, the senior vice president now owns 12,500 shares of the company’s stock, valued at approximately $623,250. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Supernus Pharmaceuticals, Inc. (NASDAQ SUPN) opened at 48.35 on Wednesday. Supernus Pharmaceuticals, Inc. has a 52-week low of $17.25 and a 52-week high of $49.95. The company’s 50-day moving average price is $43.68 and its 200-day moving average price is $37.06. The company has a market cap of $2.45 billion, a price-to-earnings ratio of 24.39 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.08. The firm had revenue of $75.83 million during the quarter, compared to analyst estimates of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. Equities research analysts expect that Supernus Pharmaceuticals, Inc. will post $1.04 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.thestockobserver.com/2017/09/13/padmanabh-p-bhatt-sells-5000-shares-of-supernus-pharmaceuticals-inc-supn-stock.html.

SUPN has been the subject of a number of research analyst reports. Piper Jaffray Companies upgraded Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the company from $30.00 to $44.00 in a research note on Thursday, June 1st. BidaskClub upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Jefferies Group LLC raised their target price on Supernus Pharmaceuticals from $35.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, May 31st. Cantor Fitzgerald raised their target price on Supernus Pharmaceuticals from $34.00 to $49.00 and gave the company a “buy” rating in a research note on Wednesday, July 5th. Finally, Zacks Investment Research cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $48.29.

A number of institutional investors have recently bought and sold shares of the business. Pinebridge Investments L.P. lifted its holdings in Supernus Pharmaceuticals by 1.3% during the second quarter. Pinebridge Investments L.P. now owns 6,624 shares of the specialty pharmaceutical company’s stock worth $285,000 after buying an additional 86 shares during the period. Louisiana State Employees Retirement System lifted its holdings in Supernus Pharmaceuticals by 0.5% during the second quarter. Louisiana State Employees Retirement System now owns 20,500 shares of the specialty pharmaceutical company’s stock worth $884,000 after buying an additional 100 shares during the period. Arizona State Retirement System lifted its holdings in Supernus Pharmaceuticals by 0.4% during the second quarter. Arizona State Retirement System now owns 26,201 shares of the specialty pharmaceutical company’s stock worth $1,129,000 after buying an additional 100 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Supernus Pharmaceuticals by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 36,650 shares of the specialty pharmaceutical company’s stock worth $1,579,000 after buying an additional 128 shares during the period. Finally, Texas Permanent School Fund lifted its holdings in Supernus Pharmaceuticals by 0.5% during the first quarter. Texas Permanent School Fund now owns 36,288 shares of the specialty pharmaceutical company’s stock worth $1,136,000 after buying an additional 178 shares during the period. Institutional investors own 95.38% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply